Laboratory of Chemical Carcinogenesis and Pharmacogenetics (Chilean Health Council Diagnostic Covid19 Laboratory), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile
Laboratory of Chemical Carcinogenesis and Pharmacogenetics (Chilean Health Council Diagnostic Covid19 Laboratory), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile
Laboratory of Chemical Carcinogenesis and Pharmacogenetics (Chilean Health Council Diagnostic Covid19 Laboratory), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile
Centro de Biotecnología Acuícola, Facultad de Química y Biología, Santiago, Chile; Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile
Centro de Biotecnología Acuícola, Facultad de Química y Biología, Santiago, Chile; Departamento de Biología, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile
Centro de Biotecnología Acuícola, Facultad de Química y Biología, Santiago, Chile; Departamento de Biología, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile; Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain; Facultad de Medicina Veterinaria y Agronomía, Universidad de Las Américas, Providencia, Chile
Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain; Department of Microbiology, Virology and Infection Control, Hospital National Health Service Foundation Trust, London, United Kingdom; National Institute for Health Research Biomedical Research Centre at Great Ormond Hospital for Children National Health Service Foundation Trust and University College, London, United Kingdom
Laboratory of Chemical Carcinogenesis and Pharmacogenetics (Chilean Health Council Diagnostic Covid19 Laboratory), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile
The COVID-19 pandemic will likely take years to control globally, and constant epidemic surveillance will be required to limit the spread of SARS-CoV-2, especially considering the emergence of new variants that could hamper the effect of vaccination efforts. We developed a simple and robust – Phone Screen Testing (PoST) – method to detect SARS-CoV-2-positive individuals by RT-PCR testing of smartphone screen swab samples. We show that 81.3–100% of individuals with high-viral-load SARS-CoV-2 nasopharyngeal-positive samples also test positive for PoST, suggesting this method is effective in identifying COVID-19 contagious individuals. Furthermore, we successfully identified polymorphisms associated with SARS-CoV-2 Alpha, Beta, and Gamma variants, in SARS-CoV-2-positive PoST samples. Overall, we report that PoST is a new non-invasive, cost-effective, and easy-to-implement smartphone-based smart alternative for SARS-CoV-2 testing, which could help to contain COVID-19 outbreaks and identification of variants of concern in the years to come.